94 related articles for article (PubMed ID: 21173337)
21. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon.
Nakayama J; Takeuchi M; Mayumi H; Nagae S; Matsuda K; Yasui H; Takahashi S; Hori Y
J Dermatol; 1996 Jan; 23(1):6-15. PubMed ID: 8720252
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib-induced premalignant and malignant skin lesions.
Williams VL; Cohen PR; Stewart DJ
Int J Dermatol; 2011 Apr; 50(4):396-402. PubMed ID: 21413947
[TBL] [Abstract][Full Text] [Related]
23. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib: atypical cutaneous side effects.
Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
[No Abstract] [Full Text] [Related]
25. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Kamada P; Dudek AZ
Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
28. Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
Moncrieff M; Shannon K; Hong A; Hersey P; Thompson J
Melanoma Res; 2008 Apr; 18(2):161-2. PubMed ID: 18337654
[TBL] [Abstract][Full Text] [Related]
29. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
31. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
32. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Chung NM; Gutierrez M; Turner ML
Arch Dermatol; 2006 Nov; 142(11):1510-1. PubMed ID: 17116852
[No Abstract] [Full Text] [Related]
33. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
34. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Frieling T; Heise J; Wassilew SW
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):e1-2, 1464-6. PubMed ID: 19572243
[TBL] [Abstract][Full Text] [Related]
35. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
Robert C; Mateus C; Spatz A; Wechsler J; Escudier B
J Am Acad Dermatol; 2009 Feb; 60(2):299-305. PubMed ID: 19028406
[TBL] [Abstract][Full Text] [Related]
36. Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia.
Chiusolo P; Metafuni E; Bellesi S; Giammarco S; Za T; Laurenti L; Sorà F; Leone G; Sica S
Bone Marrow Transplant; 2012 Jun; 47(6):872-3. PubMed ID: 21927035
[No Abstract] [Full Text] [Related]
37. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
[TBL] [Abstract][Full Text] [Related]
38. Palliation of skeletal melanoma metastases with isolated limb perfusion chemotherapy.
Rajpar SF; Martin-Clavijo A; Marsden JR; Byrne D
Dermatol Surg; 2006 Sep; 32(9):1199-201. PubMed ID: 16970706
[No Abstract] [Full Text] [Related]
39. Localized dyskeratotic plaque with milia associated with sorafenib.
Chappell JA; Burkemper NM; Semchyshyn N
J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
[TBL] [Abstract][Full Text] [Related]
40. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
